GO:0034012 FAD-AMP lyase (cyclizing) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034012 FAD-AMP lyase (cyclizing) activity catalyzes the cleavage of FAD into AMP, H+, and riboflavin cyclic-4',5'-phosphate, a five-atom cyclic phosphodiester.
• The enzyme is synonymous with FMN cyclase activity and is encoded in humans and rats by TKFC (also known as DAK), which also functions as an ATP-dependent dihydroxyacetone kinase.
• Substrate specificity studies show a strong preference for FAD over other ribonucleoside diphosphate-X compounds, and the reaction produces a cyclic phosphodiester rather than a linear product.
• TKFC variants have been linked to isolated immunodeficiency and to altered fructose metabolism, highlighting the physiological importance of this dual-activity enzyme.
• The enzyme is regulated at the transcriptional level by ChREBP and HNF4α, connecting FAD-AMP lyase activity to metabolic gene networks.
• Studying GO:0034012 requires integrating enzymatic assays, CRISPR knockout/knock-in models, and metabolomics to dissect its role in flavin and fructose metabolism.
Description
FAD-AMP lyase (cyclizing) activity, classified under GO:0034012, is a molecular function that catalyzes the breakdown of flavin adenine dinucleotide (FAD) into AMP, a proton, and riboflavin cyclic-4',5'-phosphate. This unusual reaction generates a cyclic phosphodiester product, distinguishing it from canonical FAD hydrolases and linking it to flavin cofactor recycling and nucleotide metabolism. The enzyme responsible for this activity in mammals is TKFC (triokinase and FMN cyclase), a bifunctional protein that also acts as an ATP-dependent dihydroxyacetone kinase. Because TKFC participates in both fructose metabolism and flavin homeostasis, its FAD-AMP lyase activity has attracted interest in metabolic disorders, immune function, and cancer biology. Researchers studying flavin-dependent processes, redox regulation, or metabolic reprogramming need reliable tools to interrogate GO:0034012 in cellular models. This article summarizes the authoritative definition, catalytic mechanism, key genes, disease associations, and experimental strategies for investigating FAD-AMP lyase (cyclizing) activity.
FAD-AMP lyase (cyclizing) activity At A Glance
| GO ID | GO:0034012 |
|---|---|
| GO term | FAD-AMP lyase (cyclizing) activity |
| Ontology | molecular_function |
| Synonym | FMN cyclase activity; FAD AMP-lyase (cyclic-FMN-forming) activity; FAD AMP-lyase (riboflavin-cyclic-4',5'-phosphate-forming) activity |
| Definition | Catalysis of the reaction: FAD = AMP + H+ + riboflavin cyclic-4',5'-phosphate. |
| Major function | Cleavage of FAD into AMP and riboflavin cyclic-4',5'-phosphate, contributing to flavin cofactor recycling and nucleotide metabolism. |
| Representative enzyme | TKFC (triokinase and FMN cyclase) in humans and rats. |
| Substrate preference | Strong preference for FAD over other ribonucleoside diphosphate-X compounds. |
| Product | Riboflavin cyclic-4',5'-phosphate, a five-atom cyclic phosphodiester. |
What Is GO:0034012?
GO:0034012 describes an enzymatic activity that catalyzes the chemical reaction FAD = AMP + H+ + riboflavin cyclic-4',5'-phosphate. In other words, the enzyme cleaves FAD into AMP and a cyclic form of riboflavin phosphate, releasing a proton. This activity is also known as FMN cyclase activity or FAD AMP-lyase (cyclic-FMN-forming) activity. The reaction is unusual because it produces a five-membered cyclic phosphodiester rather than a linear mononucleotide, and the enzyme shows a strong preference for FAD as substrate.
Why Is FAD-AMP lyase (cyclizing) activity Important in Cell Biology?
FAD-AMP lyase (cyclizing) activity is important because it sits at the intersection of flavin metabolism and carbohydrate metabolism. The enzyme TKFC, which carries this activity, is a bifunctional protein that also phosphorylates dihydroxyacetone, a key intermediate in fructose metabolism. This dual role means that alterations in GO:0034012 can influence both flavin cofactor availability and metabolic flux through fructose, with downstream effects on lipid synthesis and energy homeostasis. Moreover, mutations in TKFC that abolish triokinase activity have been linked to isolated immunodeficiency, underscoring the physiological relevance of this enzyme in immune function. Understanding GO:0034012 therefore provides insights into metabolic disorders, immune deficiencies, and potential therapeutic targets.
• Provides a route for FAD recycling by generating riboflavin cyclic-4',5'-phosphate, which may be further metabolized.
• TKFC, the enzyme with this activity, is also an ATP-dependent dihydroxyacetone kinase involved in fructose metabolism.
• Dysregulation of TKFC has been implicated in metabolic dysfunction-associated steatotic liver disease through effects on glycerol-3-phosphate acyltransferase 3.
• The TKFC Ala185Thr variant, previously considered null for fructose metabolism, retains full triokinase activity, highlighting the need to distinguish between activities.
• Homozygous TKFC variants that abolish triokinase activities are associated with isolated immunodeficiency, linking the enzyme to immune cell function.
• TKFC expression is regulated by ChREBP and HNF4α, connecting GO:0034012 to transcriptional networks controlling glucose and lipid metabolism.
• Inhibition of TKFC by magnolol reduces high fructose-induced podocyte inflammation, suggesting a role in kidney injury.
• The unusual cyclic phosphodiester product makes this activity a unique target for chemical biology and inhibitor design.
• Studying GO:0034012 can reveal crosstalk between flavin homeostasis and metabolic signaling pathways.
• CRISPR-based models of TKFC can help dissect the specific contribution of FAD-AMP lyase activity versus triokinase activity in disease.
Molecular Mechanism of FAD-AMP lyase (cyclizing) activity
Substrate recognition and binding
In simple terms: The enzyme grabs FAD and holds it in place to break it apart.
FAD-AMP lyase (cyclizing) activity shows a strong preference for FAD as substrate over other ribonucleoside diphosphate-X compounds. The enzyme binds FAD and positions it for cleavage between the AMP moiety and the riboflavin cyclic phosphate portion. Substrate specificity studies using analogs revealed that modifications to the flavin ring or the phosphate groups reduce activity, indicating precise molecular recognition.
Catalytic cleavage and cyclic phosphodiester formation
In simple terms: The enzyme cuts FAD into two pieces, one of which forms a ring.
The catalytic mechanism involves the cleavage of the phosphoanhydride bond in FAD, releasing AMP and a proton, while the riboflavin moiety cyclizes to form riboflavin cyclic-4',5'-phosphate. This product is a five-atom cyclic phosphodiester, which is chemically distinct from the linear FMN produced by other enzymes. The reaction is reversible in principle, but the enzyme predominantly catalyzes the lyase direction.
Bifunctional enzyme context: TKFC
In simple terms: The same protein that does this reaction also has a second job in sugar metabolism.
In humans and rats, FAD-AMP lyase (cyclizing) activity is carried out by TKFC (triokinase and FMN cyclase), a bifunctional enzyme that also possesses ATP-dependent dihydroxyacetone kinase activity. This dual functionality means that the protein can switch between flavin metabolism and fructose metabolism depending on substrate availability and cellular context. The two activities reside in distinct domains, allowing independent regulation and function.
Cofactors and metal requirements
In simple terms: The enzyme does not need extra helper molecules beyond FAD itself.
The FAD-AMP lyase reaction does not require additional cofactors or metal ions; FAD serves as both substrate and source of the flavin product. This simplicity distinguishes it from many other lyases that depend on divalent cations or coenzymes. The reaction releases a proton, which can affect local pH and may influence enzyme activity.
Regulation of TKFC expression
In simple terms: The amount of the enzyme in cells is controlled by metabolic transcription factors.
TKFC expression is regulated at the transcriptional level by ChREBP and HNF4α, which are key transcription factors in glucose and lipid metabolism. ChREBP activates the TKFC promoter in response to carbohydrate availability, while HNF4α is required for this activation. This regulatory link connects FAD-AMP lyase activity to nutritional status and metabolic gene networks.
Key Genes Involved in GO:0034012 FAD-AMP lyase (cyclizing) activity
The following genes and proteins are directly or indirectly involved in FAD-AMP lyase (cyclizing) activity, its regulation, and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TKFC | Encodes the bifunctional enzyme with FAD-AMP lyase (cyclizing) and triokinase activities | Primary gene for GO:0034012; mutations linked to immunodeficiency and metabolic traits |
| ChREBP (MLXIPL) | Transcription factor activating TKFC promoter in response to carbohydrates | Regulates TKFC expression and links to fructose metabolism |
| HNF4α (HNF4A) | Transcription factor required for ChREBP-mediated TKFC promoter activation | Controls TKFC expression in liver and metabolic contexts |
| GPAT3 | Glycerol-3-phosphate acyltransferase 3, involved in lipid synthesis | Downstream target affected by TKFC modulation in steatotic liver disease |
| Sp1 | Transcription factor implicated in TKFC-related podocyte inflammation | Potential mediator of TKFC effects in kidney cells |
| HDAC4 | Histone deacetylase 4, involved in Notch1 regulation | Part of TKFC/Sp1/HDAC4/Notch1 axis in podocytes |
| Notch1 | Signaling receptor involved in cell fate and inflammation | Activated downstream of TKFC in high fructose conditions |
| DAK | Alternative name for TKFC in some contexts | Same gene product as TKFC; relevant for dihydroxyacetone kinase activity |
| FAD | Substrate of the reaction | Central flavin cofactor; its cleavage produces AMP and cyclic riboflavin phosphate |
| AMP | Product of the reaction | Nucleotide released during FAD cleavage |
| Riboflavin cyclic-4',5'-phosphate | Product of the reaction | Unusual cyclic phosphodiester; potential signaling molecule |
| FMN | Related flavin mononucleotide | Product of FMN cyclase activity synonym; distinct from cyclic product |
| ATP | Cofactor for triokinase activity of TKFC | Required for the dihydroxyacetone kinase function of the same enzyme |
| Dihydroxyacetone | Substrate for triokinase activity | Metabolic intermediate in fructose metabolism |
| Fructose | Dietary sugar linked to TKFC function | High fructose conditions modulate TKFC-related pathways |
| Curcumin | Natural compound targeting TKFC | Modulates TKFC/FMN cyclase in steatotic liver disease models |
| Magnolol | Natural compound inhibiting TKFC | Reduces podocyte inflammation via TKFC downregulation |
How Is FAD-AMP lyase (cyclizing) activity Regulated?
TKFC expression is regulated by the transcription factors ChREBP and HNF4α, which respond to carbohydrate availability and metabolic status. ChREBP activates the TKFC promoter, and HNF4α is required for this activation, linking FAD-AMP lyase activity to glucose and lipid metabolic networks. Additionally, the enzyme's bifunctional nature means that its FAD-AMP lyase activity may be modulated by substrate availability, as FAD competes with dihydroxyacetone for binding to the same protein. Post-translational modifications and cellular localization could also influence activity, though specific mechanisms remain to be fully elucidated.
FAD-AMP lyase (cyclizing) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TKFC | Metabolic dysfunction-associated steatotic liver disease | Hepatocyte-specific TKFC knockout or knock-in of patient variants |
| TKFC | Isolated immunodeficiency | Lymphocyte or macrophage models with TKFC mutations |
| TKFC | Podocyte inflammation and kidney injury | Podocyte cell lines with TKFC overexpression or knockdown |
| TKFC | Fructose metabolism disorders | CRISPR knock-in of Ala185Thr variant in cell lines |
| GPAT3 | Lipid synthesis and steatosis | GPAT3 reporter assays in TKFC-modulated cells |
Metabolic dysfunction-associated steatotic liver disease (MASLD)
TKFC/FMN cyclase has been identified as a target of curcumin in ameliorating metabolic dysfunction-associated steatotic liver disease. Curcumin modulates TKFC to regulate the expression of glycerol-3-phosphate acyltransferase 3 (GPAT3), integrating chemical proteomics and transcriptomics data. This suggests that FAD-AMP lyase activity may influence lipid synthesis and hepatic steatosis through downstream effects on GPAT3.
Isolated immunodeficiency
Homozygous variants in TKFC that abolish triokinase activities have been associated with isolated immunodeficiency, highlighting the importance of this enzyme in immune function. Although the specific contribution of FAD-AMP lyase activity to this phenotype is not fully defined, the dual-activity nature of TKFC suggests that both flavin and fructose metabolism may impact immune cell function.
Kidney injury and podocyte inflammation
Magnolol inhibits high fructose-induced podocyte inflammation via downregulation of the TKFC/Sp1/HDAC4/Notch1 axis. This implicates TKFC, and potentially its FAD-AMP lyase activity, in kidney podocyte injury and inflammation under high fructose conditions.
Fructose metabolism disorders
The TKFC Ala185Thr variant, previously reported as null for fructose metabolism, was found to be fully active as triokinase, indicating that not all TKFC variants impair both activities. This distinction is important for understanding genotype-phenotype relationships in fructose-related disorders and for interpreting the role of FAD-AMP lyase activity in metabolic disease.
From FAD-AMP lyase (cyclizing) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TKFC knockout abolish FAD-AMP lyase activity? | TKFC knockout cell lines generated by CRISPR |
| How does the Ala185Thr variant affect FAD-AMP lyase vs triokinase activity? | Point mutation knock-in of Ala185Thr in TKFC |
| Can we tag endogenous TKFC to study localization? | Knock-in of fluorescent or epitope tags at the TKFC locus |
| What is the effect of TKFC overexpression on flavin metabolism? | TKFC overexpression cell lines |
| Which genes are regulated by TKFC in liver cells? | CRISPR knockout combined with RNA-seq |
| Does TKFC modulation affect Notch1 signaling in podocytes? | Podocyte cell lines with TKFC knockdown or overexpression |
How to Study the FAD-AMP lyase (cyclizing) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC-based enzyme assay | Conversion of FAD to AMP and cyclic riboflavin phosphate | Purified enzyme kinetics and inhibitor testing |
| CRISPR knockout | Loss of TKFC protein and both enzymatic activities | Phenotypic studies in metabolic and immune cells |
| CRISPR knock-in | Introduction of specific TKFC variants | Dissecting activity-specific effects of mutations |
| RNA-seq | Global transcriptional changes | Identifying downstream pathways regulated by TKFC |
| Chemical proteomics | Protein targets of small molecules like curcumin | Discovering TKFC as a drug target |
| Metabolomics | Levels of FAD, FMN, and fructose metabolites | Assessing metabolic impact of TKFC modulation |
| Western blot | TKFC protein expression and modification | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization of TKFC | Studying compartmentalization of FAD-AMP lyase activity |
Enzymatic assays for FAD-AMP lyase activity
Direct measurement of FAD-AMP lyase (cyclizing) activity can be performed using purified enzyme or cell lysates, monitoring the conversion of FAD to AMP and riboflavin cyclic-4',5'-phosphate by HPLC or mass spectrometry. Substrate specificity studies using FAD analogs can reveal structural requirements for catalysis.
CRISPR-based genetic models
CRISPR knockout, knock-in, and point mutation models of TKFC allow researchers to dissect the specific contribution of FAD-AMP lyase activity to cellular phenotypes. For example, knocking out TKFC abolishes both FAD-AMP lyase and triokinase activities, while knock-in of specific variants can separate the two functions.
Transcriptomics and proteomics
RNA-seq and proteomics can identify downstream targets and pathways affected by TKFC modulation. Chemical proteomics combined with transcriptomics has been used to identify GPAT3 as a downstream effector of curcumin-targeted TKFC in steatotic liver disease.
Metabolomics and flux analysis
Metabolomic profiling can measure changes in flavin nucleotides (FAD, FMN) and fructose metabolites upon modulation of TKFC activity. This approach helps link FAD-AMP lyase activity to metabolic flux and energy homeostasis.
How CRISPR Can Be Used to Study GO:0034012 FAD-AMP lyase (cyclizing) activity
Knockout
CRISPR knockout of TKFC eliminates both FAD-AMP lyase (cyclizing) and triokinase activities, providing a clean background to study the consequences of losing this bifunctional enzyme. Knockout cell lines can be used to assess changes in flavin nucleotide pools, fructose metabolism, and downstream signaling pathways.
Point Mutation
Point mutation knock-in of specific TKFC variants, such as Ala185Thr, allows researchers to separate the effects of FAD-AMP lyase activity from triokinase activity. This approach is valuable for understanding how disease-associated mutations differentially affect the two enzymatic functions.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous TKFC locus enables real-time tracking of enzyme localization and interaction partners without altering expression levels. This can reveal where FAD-AMP lyase activity occurs within the cell and how it is regulated spatially.
Overexpression
Overexpression of wild-type or mutant TKFC in cell lines can amplify FAD-AMP lyase activity, making it easier to detect downstream metabolic changes and to test inhibitors. Overexpression models are particularly useful for studying the enzyme's role in lipid synthesis and inflammation.
How EDITGENE Supports FAD-AMP lyase (cyclizing) activity Research
Researchers studying FAD-AMP lyase (cyclizing) activity-related genes often need to determine whether a candidate gene is causally involved in a specific metabolic or immune phenotype. This requires precise genetic models that can isolate the contribution of individual enzymatic activities, such as the FAD-AMP lyase versus triokinase functions of TKFC. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for FAD-AMP lyase (cyclizing) activity research.
Frequently Asked Questions About FAD-AMP lyase (cyclizing) activity
What is FAD-AMP lyase (cyclizing) activity?
FAD-AMP lyase (cyclizing) activity is an enzymatic function, classified as GO:0034012, that catalyzes the cleavage of FAD into AMP, a proton, and riboflavin cyclic-4',5'-phosphate.
What genes are involved in FAD-AMP lyase (cyclizing) activity?
The primary gene encoding this activity in humans and rats is TKFC, which also functions as an ATP-dependent dihydroxyacetone kinase.
What is the reaction catalyzed by GO:0034012?
The reaction is FAD = AMP + H+ + riboflavin cyclic-4',5'-phosphate, producing a unique cyclic phosphodiester product.
Is FAD-AMP lyase the same as FMN cyclase?
Yes, FMN cyclase activity is a synonym for FAD-AMP lyase (cyclizing) activity, reflecting the formation of a cyclic flavin mononucleotide derivative.
What diseases are associated with TKFC mutations?
TKFC mutations have been linked to isolated immunodeficiency and metabolic dysfunction-associated steatotic liver disease, among other conditions.
How is TKFC expression regulated?
TKFC expression is regulated by the transcription factors ChREBP and HNF4α in response to carbohydrate availability.
What is the difference between FAD-AMP lyase and triokinase activities of TKFC?
FAD-AMP lyase activity cleaves FAD into AMP and cyclic riboflavin phosphate, while triokinase activity phosphorylates dihydroxyacetone using ATP; both are carried out by the same protein.
Can CRISPR be used to study FAD-AMP lyase activity?
Yes, CRISPR knockout, knock-in, and point mutation models of TKFC allow precise dissection of FAD-AMP lyase function in cells.
What is the product of FAD-AMP lyase (cyclizing) activity?
The products are AMP, a proton, and riboflavin cyclic-4',5'-phosphate, a five-atom cyclic phosphodiester.
Why is FAD-AMP lyase activity important for metabolism?
It connects flavin cofactor recycling with fructose metabolism through the bifunctional enzyme TKFC, influencing lipid synthesis and energy homeostasis.
Conclusion
FAD-AMP lyase (cyclizing) activity (GO:0034012) represents a unique enzymatic function that bridges flavin and carbohydrate metabolism through the bifunctional enzyme TKFC. Its unusual cyclic phosphodiester product and dual role in fructose metabolism make it a compelling target for metabolic and immune research. Understanding its regulation, disease associations, and catalytic mechanism requires robust experimental models, including CRISPR-based knockouts, knock-ins, and overexpression systems. EDITGENE provides the tools and expertise to accelerate discoveries in this emerging field.
References
- 1. Cabezas A et al.. 2001. Purification, characterization, and substrate and inhibitor structure-activity studies of rat liver FAD-AMP lyase (cyclizing): preference for FAD and specificity for splitting ribonucleoside diphosphate-X into ribonucleotide and a five-atom cyclic phosphodiester of X, either a monocyclic compound or a cis-bicyclic phosphodiester-pyranose fusion.. Biochemistry 40(45):13710-22 PMID: 11695920
- 3. Cabezas A et al.. 2005. Identification of human and rat FAD-AMP lyase (cyclic FMN forming) as ATP-dependent dihydroxyacetone kinases.. Biochem Biophys Res Commun 338(4):1682-9 PMID: 16289032
- 4. Zhao C et al.. 2026. Curcumin ameliorates metabolic dysfunction-associated steatotic liver disease via targeting triokinase/FMN cyclase to regulate the expression of glycerol-3-phosphate acyltransferase 3: Integration of chemical proteomics and transcriptomics.. Acta Pharm Sin B 16(5):3026-3042 PMID: 42180525
- 5. Tsukamoto R et al.. 2024. HNF4α is required for Tkfc promoter activation by ChREBP.. Biosci Biotechnol Biochem 88(8):941-947 PMID: 38782732
- 6. Ribeiro JM et al.. 2022. The TKFC Ala185Thr variant, reported as 'null' for fructose metabolism, is fully active as triokinase.. FEBS Lett 596(11):1453-1457 PMID: 35114011
- 7. Tremblay-Laganière C et al.. 2024. Homozygous variant in TKFC abolishing triokinase activities is associated with isolated immunodeficiency.. J Med Genet 61(9):886-890 PMID: 38697782
- 8. Zhou Z et al.. 2024. Magnolol Inhibits High Fructose-Induced Podocyte Inflammation via Downregulation of TKFC/Sp1/HDAC4/Notch1 Activation.. Pharmaceuticals (Basel) 17(11) PMID: 39598328
